<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253015</url>
  </required_header>
  <id_info>
    <org_study_id>EUSA DB 0001</org_study_id>
    <nct_id>NCT04253015</nct_id>
  </id_info>
  <brief_title>A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta</brief_title>
  <official_title>A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EusaPharma (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United BioSource, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EusaPharma (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, multi-national, observational, prospective patient registry to&#xD;
      further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal&#xD;
      immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and&#xD;
      incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular&#xD;
      events, hypersensitivity reactions and long-term safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and Background:&#xD;
&#xD;
      Neuroblastoma, is the most common extra-cranial solid tumour in children. Most patients with&#xD;
      neuroblastoma are diagnosed under the age of 5 years and most present with metastatic disease&#xD;
      and/or high-risk features. Despite the introduction of novel treatment strategies, including&#xD;
      high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), the outcome&#xD;
      of these patients remains poor.&#xD;
&#xD;
      Dinutuximab beta is a chimeric monoclonal immunoglobulin G 1 (IgG1) antibody that is&#xD;
      specifically directed against the carbohydrate moiety of disialoganglioside antigen (GD2),&#xD;
      which is overexpressed on neuroblastoma cells. By binding to neuroblastoma cells, dinutuximab&#xD;
      beta can induce both complement dependent cytotoxicity (CDC) and antibody dependent&#xD;
      cell-mediated cytotoxicity (ADCC).&#xD;
&#xD;
      The efficacy of dinutuximab beta has been evaluated in a randomised controlled trial&#xD;
      comparing the administration of dinutuximab beta with or without interleukin 2 (IL-2) in the&#xD;
      first-line treatment of patients with high-risk neuroblastoma and in two singlearm studies in&#xD;
      the relapsed/refractory setting. The efficacy and safety of dinutuximab beta will further be&#xD;
      evaluated in this registry that will provide information on survival, pain severity and&#xD;
      incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular&#xD;
      events, hypersensitivity reactions and long-term safety.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This is a non-interventional, multi-national, observational, prospective patient registry of&#xD;
      patients with high-risk neuroblastoma being treated with the monoclonal antibody dinutuximab&#xD;
      beta. The efficacy and safety of dinutuximab beta will further be evaluated in this registry&#xD;
      that will provide information on survival, pain severity and incidence of neurotoxicity,&#xD;
      visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions&#xD;
      and long-term safety.&#xD;
&#xD;
      Research Questions and Objectives:&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  To assess pain severity and use of analgesics during the period of first dose of&#xD;
           dinutuximab beta to end of last 35 day course of the 5th cycle of treatment&#xD;
&#xD;
        -  To assess the incidence of neurotoxicity, visual impairment, capillary leak syndrome,&#xD;
           cardiovascular events and hypersensitivity reactions&#xD;
&#xD;
        -  To assess the long term safety profile&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Progression free survival (PFS) in patients treated with dinutuximab beta.&#xD;
&#xD;
        -  Event Free Survival (EFS) in patients treated with dinutuximab beta&#xD;
&#xD;
        -  Overall survival (OS) in patients treated with dinutuximab beta&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab&#xD;
      beta in the standard clinical practice setting or participating in a clinical trial where&#xD;
      dinutuximab beta is provided according to the indication as per the country/regional&#xD;
      marketing authorisation, provide consent/assent and are willing to be followed up for up to&#xD;
      10 years.&#xD;
&#xD;
      Study Size:&#xD;
&#xD;
      It is planned to enroll a sufficient number of patients (estimated at 125) such that 100&#xD;
      patients will have completed all five treatment courses of dinutuximab beta. It is&#xD;
      anticipated that this will result in 40-50 patients who are progression free at 10 years.&#xD;
&#xD;
      Data Sources:&#xD;
&#xD;
      Data will be collected from physicians using an electronic data capture (EDC) system. The&#xD;
      electronic case report forms (eCRFs) will be designed to gather data from the medical records&#xD;
      at baseline, during treatment and at normal clinical practice follow up visits.&#xD;
&#xD;
      Data Analysis:&#xD;
&#xD;
      The safety analysis set, containing all patients treated with at least one dose of&#xD;
      dinutuximab beta will be considered for safety and efficacy analyses. All baseline, treatment&#xD;
      period and follow up characteristics will be summarized using descriptive statistics.&#xD;
      Endpoints addressing primary and secondary analysis will include 95% confidence intervals&#xD;
      (CIs) including the Clopper Pearson method for binomial, log-log transform for survival. OS,&#xD;
      PFS and EFS will be analysed using Kaplan-Meier methods.&#xD;
&#xD;
      Variables:&#xD;
&#xD;
      Baseline (prior to start of treatment): Demographics, clinical trial participation,&#xD;
      neuroblastoma disease history, and presence or absence of neurotoxicity, visual impairment,&#xD;
      and cardiovascular abnormality.&#xD;
&#xD;
      Treatment period (up to end of last 35 day course of 5th cycle of treatment):&#xD;
&#xD;
      Dosing regimen, total cumulative amount of dinutuximab beta per course, concomitant&#xD;
      medications during course (IL-2, retinoic acid and/or antihistamines), daily analgesics&#xD;
      (opioids, gabapentin/ pregabalin and/or non-opioid analgesics and other neuropathic pain&#xD;
      treatments), daily pain assessment during infusion of dinutuximab beta, occurrence of&#xD;
      neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, and&#xD;
      hypersensitivity reactions, adverse events (AEs)/serious adverse events (SAEs) treatment&#xD;
      interruptions and discontinuations, progression of disease, date and cause of death, reason&#xD;
      for study withdrawal (if applicable) Follow up (from end of last 35 day course of 5th cycle&#xD;
      of treatment): Status of neurotoxicity, visual impairment, cardiovascular events, (resolved,&#xD;
      not resolved), SAEs and adverse drug reaction (ADRs), progression of disease, date and cause&#xD;
      of death, reason for study withdrawal (if applicable).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2032</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2032</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Assessment of the severity of pain experienced by participants during treatment with dinutuximab beta</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Assessment of pain severity experienced by participants during the period of first dose of dinutuximab beta to the end of last 35 day course of 5th cycle of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants using analgesics during treatment with dinutuximab beta</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of 5th cycle of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions up to the end of the last 35 day course of 5th cycle of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) during treatment with dinutuximab beta</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) following the end of the last 35 day course of 5th cycle of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Overall Survival (OS) following the end of the last 35 day course of 5th cycle of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Progression free survival (PFS) following the end of the last 35 day course of 5th cycle of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)</time_frame>
    <description>Event Free Survival (EFS) following the end of the last 35 day course of 5th cycle of treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data-collection</intervention_name>
    <description>Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab&#xD;
        beta in the standard clinical practice setting or participating in a clinical trial where&#xD;
        dinutuximab beta is provided according to the indication as per the country/regional&#xD;
        marketing authorisation, provide consent/assent and are willing to be followed up for up to&#xD;
        10 years. Centers who treat neuroblastoma patients with dinutuximab beta will be invited to&#xD;
        participate in the registry. This includes networks such as the Society of Paediatric&#xD;
        Oncology for the Treatment of Neuroblastoma (SIOPEN) in Europe.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients meeting the following criteria will be considered for inclusion into the registry:&#xD;
&#xD;
          -  Patients diagnosed with high-risk neuroblastoma and starting treatment with&#xD;
             commercially available dinutuximab beta OR&#xD;
&#xD;
          -  Patients diagnosed with high-risk neuroblastoma and starting treatment with&#xD;
             dinutuximab beta in a clinical trial where dinutuximab beta is provided according to&#xD;
             the country/regional marketing authorisation AND&#xD;
&#xD;
          -  Appropriate consent/assent has been obtained for participation in the registry with a&#xD;
             willingness to be followed up for up to 10 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient will not be eligible for inclusion if the following criterion applies:&#xD;
&#xD;
          -  Patients commencing dinutuximab beta within a clinical trial where the product is&#xD;
             being provided outside of the country/regional marketing authorisation OR&#xD;
&#xD;
          -  Appropriate consent/assent has not been obtained for participation in the registry or&#xD;
             patient/legal representative is not willing for the patient be followed up for up to&#xD;
             10 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Alvarez Rojo, Dr</last_name>
    <role>Study Director</role>
    <affiliation>EUSA Pharma (UK) Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Alvarez Rojo, Dr</last_name>
    <phone>+34 677 61 48 58</phone>
    <email>Ignacio.AlvarezRojo@eusapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Anna Kinderkrebsforschung</name>
      <address>
        <city>Wien,</city>
        <state>Vienna</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Ladenstein, Dr</last_name>
      <phone>+43(1)40470-4750</phone>
      <email>ruth.ladenstein@ccri.at</email>
    </contact>
    <investigator>
      <last_name>Ruth Ladenstein, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone, Hôpital des Enfants</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imene Hazem, Mr</last_name>
      <phone>0033 1 42 11 50 20</phone>
      <email>Imene.HEZAM@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fanny Prenois, Mrs</last_name>
      <phone>0033 1 42 11 50 20</phone>
      <email>Fanny.PRENOIS@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique Valteau-Couanet, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Eggert, Dr</last_name>
      <phone>+ 49 30 450 566 808</phone>
      <email>angelika.eggert@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Deubzer, Dr</last_name>
      <phone>+ 49 30 450 566 808</phone>
      <email>heidi.deubzer@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Angelika Eggert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Deubzer, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Simon, Dr</last_name>
      <phone>+49 221-478-6850</phone>
      <email>thorsten.simon@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Landgraf, Dr</last_name>
      <phone>+49 221-478-6850</phone>
      <email>pablo.landgraf@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thorsten Simon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Landgraf, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Hero, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Zanardi</last_name>
      <phone>+39.010.5636.3461</phone>
      <email>SabrinaZanardi@gaslini.org</email>
    </contact>
    <investigator>
      <last_name>Carla Manzitti, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Garaventa, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Sorrentino, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dziecięcy</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Wieczore, Dr</last_name>
      <phone>(+48) 12 3339392</phone>
      <email>a.wieczorek@uj.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Walentyna Balwierz, Dr</last_name>
      <phone>(+48) 12 658 20 11</phone>
      <phone_ext>4321</phone_ext>
      <email>walentyna.balwierz@uj.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Aleksandra Wieczorek, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walentyna Balwierz, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Ramal</last_name>
      <phone>+34-638902615</phone>
    </contact>
    <investigator>
      <last_name>Adela Canete, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Juan Fornes, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca Martinez, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Newcastle</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoff Bell</last_name>
      <phone>0191 282 1337</phone>
      <email>Geoff.Bell@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Linda Coates</last_name>
      <phone>0191 2829964</phone>
      <email>Linda.Coates7@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Tweddle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lawrence</last_name>
      <phone>02381206334</phone>
      <email>Ruth.Lawrence@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Alice Johnson</last_name>
      <phone>02381206334</phone>
      <email>alice.johnson@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Juliet Gray, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sucheta Vaidya, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumour</keyword>
  <keyword>Brain tumour</keyword>
  <keyword>Paediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

